Osmol Therapeutics Market Research Report

Company Overview

Name and Mission of the Company

Name: Osmol Therapeutics

Mission: Enhancing care and transforming lives by creating compassionate and effective treatment paths for cancer patients at risk of developing chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI).

Founding and Leadership

When Founded: No information is available.

Founders: No information is available.

Key People:

Bob Linke, MBA - President & CEO

Barbara Ehrlich, PhD - Chief Scientific Advisor

Ron Weitzman, MD, FACP - Chief Medical Officer

Julie Straub, PhD - VP, Preclinical Development & CMC

Ann Robbins, PhD - VP, Regulatory Affairs

Gary Connor, RN - VP, Clinical Development

Headquarters

Location: New Haven, Connecticut, USA

Employees

Number of Employees: No information is available.

Revenue

Revenue: No information is available.

Core Competency

Known For: Developing first-in-class preventative treatments for CIPN and CICI, conditions significantly impacting quality of life and survival for cancer patients.

Products

Current Offerings

OSM-0205: A patented drug designed to prevent the onset of CIPN and CICI in cancer patients undergoing chemotherapy.

High-Level Description: Administered intravenously before chemotherapy to target and prevent the neuronal damage associated with CIPN and CICI.

Key Features:

Blocks calcium surge and prevents neuronal damage.

Helps maintain cognitive function and neuronal integrity.

Prevents pathological and behavioral symptoms in animal models.

Recent Developments

New Appointments

Christopher S. Eklund joined the Board of Directors on May 15, 2024.

Ron Weitzman, M.D. appointed as Interim Chief Medical Officer on March 4, 2024.

Teresa Bitetti joined the Board of Directors on September 8, 2022.

Future Plans

Clinical Trials:

An FDA green light was given on September 18, 2023, for the first-in-human Phase 1 Clinical Trial of OSM-0205 to prevent CIPN.

Clinical program initiation is planned for mid-2024, to be followed by a Phase 2 study for CIPN prevention in breast cancer patients.

Partnerships and Funding

In April of 2022, Osmol Therapeutics closed a Series A-1 Funding round to advance the clinical development of OSM-0205 for chemotherapy-induced neuropathy.

Conferences and Presentations

Participated in BIOTECH SHOWCASE 2023 from January 9-11 in San Francisco, highlighting therapeutic advancements.

Press Coverage

Recent press releases between 2021 and 2024 highlight key appointments and advancements in OSM-0205's clinical development.

Conclusion

Osmol Therapeutics remains committed to innovating and advancing treatments that aim to prevent the debilitating effects of chemotherapy on cancer patients, ensuring better therapeutic outcomes and improved quality of life through its groundbreaking product, OSM-0205.